STOCK TITAN

Zevra Therapeutics Inc - ZVRA STOCK NEWS

Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.

Company Overview

Zevra Therapeutics Inc is a biopharmaceutical company specializing in rare diseases. By harnessing cutting-edge science, data analytics, and a deep understanding of patient needs, the company develops transformational therapies that address conditions with limited or no treatment options. With a data-driven clinical development strategy, Zevra combines innovative research with strategic commercialization efforts, addressing high unmet needs in the rare disease space and reinforcing its standing within the competitive biopharmaceutical industry.

Business Focus and Operational Model

Zevra Therapeutics is uniquely positioned as a rare disease company that emphasizes late-stage clinical development. The company has transitioned from maintaining extensive in-house drug discovery capabilities to outsourcing early research and concentrating resources on advancing clinical candidates through pivotal trials. This realignment allows Zevra to optimize its investments in clinical expertise and regulatory navigation, ensuring that its therapeutic candidates are developed with a sharp focus on patient safety and efficacy.

Transformational Therapeutic Development

At the heart of Zevra’s mission is the commitment to create life-changing medicines. The company employs a rigorous, data-driven approach to identify and optimize chemical entities for rare and complex conditions. Through state-of-the-art analysis and strategic partnerships, Zevra navigates the intricate drug development lifecycle—from early research outsourcing to late-stage clinical advancement—ensuring that potential therapeutics are developed with precision and care.

Strategic Partnerships and Collaborative Expertise

The success of Zevra Therapeutics is underpinned by collaborations with key industry experts and research institutions. These partnerships enable the company to leverage specialized knowledge and share best practices, ultimately accelerating the delivery of novel therapies to patients. By integrating external expertise with its in-house clinical development capabilities, Zevra is well-equipped to overcome the inherent challenges of rare disease treatment development.

Commitment to Patients and Industry Impact

Driven by the goal of significantly impacting patient lives, Zevra Therapeutics prioritizes therapies that address serious and rare conditions. The company’s dedication to addressing unmet medical needs is demonstrated by its robust data analytics and patient-centric strategies, aligning therapeutic innovation with clinical and commercial viability. Investors and industry analysts recognize Zevra for its methodical approach, which combines scientific precision with the strategic agility required to navigate the complex biopharmaceutical landscape.

Key Highlights

  • Focus on Rare Diseases: Zevra specializes in conditions with limited treatment options, ensuring focused R&D for challenging therapeutic areas.
  • Data-Driven Strategy: The incorporation of comprehensive data analytics strengthens decision-making throughout the drug development pipeline.
  • Strategic Outsourcing: By outsourcing early research, the company concentrates resources on advancing critical clinical candidates.
  • Collaborative Model: Partnerships with industry experts enhance its research capabilities and streamline the path to commercialization.
  • Patient-Centric Approach: At every stage, the company prioritizes patient needs, ensuring that therapies are both safe and effective.
Rhea-AI Summary
Zevra Therapeutics, Inc. secures a new $100M credit facility led by Perceptive Advisors and Healthcare Royalty to support its rare disease therapeutics development. The facility includes an initial draw of $60M, with additional tranches available upon meeting certain conditions. Zevra retires existing debt of $43.1M, with net proceeds of $14.0M. The five-year facility bears interest at 12.33% per annum and allows in-kind interest payments. This move aims to strengthen Zevra's financial position and advance its strategic goals for 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
none
-
Rhea-AI Summary
Zevra Therapeutics, Inc. reports strong financial results for Q4 2023 with a net revenue of $13.2M and FY 2023 net revenue of $27.5M. The company made progress in launching OLPRUVA® and preparing for arimoclomol launch. Positive data from the KP1077 phase 2 study in idiopathic hypersomnia was highlighted. The company completed the acquisition of Acer Therapeutics, Inc., enhancing its rare disease assets and revenue potential. Financially, there was an increase in net revenue, but also an increase in R&D and G&A expenses, leading to a net loss for both Q4 and FY 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.03%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. announces positive top-line data from its Phase 2 clinical trial evaluating KP1077 for idiopathic hypersomnia, showing clinically meaningful benefits for key symptoms. The study demonstrated improvements in excessive daytime sleepiness, sleep inertia, and brain fog, supporting the safety and tolerability of KP1077 for further development into a Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) to participate in the 23rd Annual Needham Virtual Healthcare Conference. Presentation scheduled for April 8, 2024, at 3:45 p.m. ET. Management team available for one-on-one investor meetings. Webcast and archived presentation details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
conferences
-
Rhea-AI Summary
Zevra Therapeutics, Inc. to host a conference call to discuss corporate and financial results for Q4 and full year 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences earnings
-
Rhea-AI Summary
Zevra Therapeutics, Inc. announces FDA extension of arimoclomol NDA review for Niemann-Pick disease type C with a new PDUFA action date of September 21, 2024. The company remains optimistic about the potential of arimoclomol to help patients despite the delay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.15%
Tags
none
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) announces Neil F. McFarlane, President and CEO, will present at investor conferences in March 2024. The company will participate in TD Cowen 44th Annual Health Care Conference and 36th Annual ROTH Conference. The live webcasts will be available on Zevra's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
-
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company's management team will also be available for one-on-one investor meetings. The live webcast will be accessible on the company's website, and the archived presentation will be available thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
conferences
-
Rhea-AI Summary
Zevra Therapeutics, Inc. appoints Alvin Shih, MD, MBA, to its Board of Directors. Dr. Shih brings extensive experience in biotechnology leadership and rare disease therapeutics development. He has held leadership roles at various biotechnology companies and has a strong background in drug development for rare diseases. Zevra's Board and management team express confidence in Dr. Shih's ability to contribute to the advancement of the company's therapeutic portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
management
Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has announced that the U.S. FDA has assigned a PDUFA action date of June 21, 2024, for the resubmission of the New Drug Application (NDA) for arimoclomol as a first-in-class treatment for Niemann-Pick disease type C. The resubmission addresses concerns previously raised in the FDA's complete response letter and includes additional evidence supporting trial metrics and data from multiple additional studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags

FAQ

What is the current stock price of Zevra Therapeutics (ZVRA)?

The current stock price of Zevra Therapeutics (ZVRA) is $7.31 as of April 22, 2025.

What is the market cap of Zevra Therapeutics (ZVRA)?

The market cap of Zevra Therapeutics (ZVRA) is approximately 376.6M.

What is the core focus of Zevra Therapeutics Inc?

Zevra Therapeutics Inc specializes in rare diseases, employing a data-driven approach to develop transformational therapies for conditions with limited treatment options.

How does Zevra Therapeutics generate its revenue?

The company focuses on advancing its clinical candidates to later stages and capitalizes on strategic partnerships and commercialization opportunities rather than in-house drug discovery.

What differentiates Zevra’s development strategy in the rare disease space?

Its emphasis on data analytics and patient-centric methodologies, coupled with a strategic outsourcing model for early research, positions Zevra uniquely within the competitive rare disease market.

How is Zevra Therapeutics structured to address complex drug development challenges?

By reallocating resources away from internal laboratories to focus on late-stage clinical development and partnering with industry experts, Zevra streamlines the path from research to commercialization.

What role do strategic partnerships play in Zevra’s operations?

Strategic partnerships enable Zevra to tap into specialized expertise and share advanced research capabilities, which are critical in accelerating the development of innovative therapies.

How does Zevra Therapeutics ensure its therapies address real patient needs?

By integrating comprehensive data analytics with a patient-centric approach, Zevra prioritizes developing safe and effective therapies that address significant and unmet medical needs in rare diseases.
Zevra Therapeutics Inc

Nasdaq:ZVRA

ZVRA Rankings

ZVRA Stock Data

376.65M
52.84M
6.83%
62.98%
10.51%
Biotechnology
Pharmaceutical Preparations
Link
United States
CELEBRATION